Search Results
Department of Endocrinology, Department of Public Health, Department of Cancer Research and Molecular Medicine, Department of Medical Biochemistry, St Olavs Hospital, Trondheim University Hospital, P O Box 3250 Sluppen, N-7006 Trondheim, Norway
Search for other papers by Bjørn O Åsvold in
Google Scholar
PubMed
Department of Endocrinology, Department of Public Health, Department of Cancer Research and Molecular Medicine, Department of Medical Biochemistry, St Olavs Hospital, Trondheim University Hospital, P O Box 3250 Sluppen, N-7006 Trondheim, Norway
Search for other papers by Valdemar Grill in
Google Scholar
PubMed
Search for other papers by Ketil Thorstensen in
Google Scholar
PubMed
Department of Endocrinology, Department of Public Health, Department of Cancer Research and Molecular Medicine, Department of Medical Biochemistry, St Olavs Hospital, Trondheim University Hospital, P O Box 3250 Sluppen, N-7006 Trondheim, Norway
Search for other papers by Marit R Bjørgaas in
Google Scholar
PubMed
Introduction The 1 mg overnight dexamethasone suppression test (DST) is a common initial test for endogenous Cushing's syndrome (1) . The principle of the test is that dexamethasone will suppress ACTH and cortisol secretion in healthy individuals
Search for other papers by Sweta Budyal in
Google Scholar
PubMed
Search for other papers by Swati Sachin Jadhav in
Google Scholar
PubMed
Search for other papers by Rajeev Kasaliwal in
Google Scholar
PubMed
Search for other papers by Hiren Patt in
Google Scholar
PubMed
Search for other papers by Shruti Khare in
Google Scholar
PubMed
Search for other papers by Vyankatesh Shivane in
Google Scholar
PubMed
Search for other papers by Anurag R Lila in
Google Scholar
PubMed
Search for other papers by Tushar Bandgar in
Google Scholar
PubMed
Search for other papers by Nalini S Shah in
Google Scholar
PubMed
participants underwent a 1 mg overnight dexamethasone suppression test (ODST) on an outpatient basis. The patients were advised to take two tablets of 0.5 mg of dexamethasone at 2300 h and the sample for cortisol was collected on the next morning between 0800
Search for other papers by Ramjan Sanas Mohamed in
Google Scholar
PubMed
Search for other papers by Biyaser Abuelgasim in
Google Scholar
PubMed
Search for other papers by Sally Barker in
Google Scholar
PubMed
Search for other papers by Hemanth Prabhudev in
Google Scholar
PubMed
Division of Diabetes, Endocrinology and Metabolism, Imperial College London, London, UK
Search for other papers by Niamh M Martin in
Google Scholar
PubMed
Division of Diabetes, Endocrinology and Metabolism, Imperial College London, London, UK
Search for other papers by Karim Meeran in
Google Scholar
PubMed
Search for other papers by Emma L Williams in
Google Scholar
PubMed
Search for other papers by Sarah Darch in
Google Scholar
PubMed
Search for other papers by Whitlock Matthew in
Google Scholar
PubMed
Division of Diabetes, Endocrinology and Metabolism, Imperial College London, London, UK
Search for other papers by Tricia Tan in
Google Scholar
PubMed
Search for other papers by Florian Wernig in
Google Scholar
PubMed
for CS including late-night salivary cortisol (LNSC), overnight dexamethasone suppression test (ODST), low-dose dexamethasone suppression test (LDDST) and 24-h urinary free cortisol (UFC) ( 1 , 2 , 3 ). A hallmark of CS is the disruption of the
University Rehabilitation Institute Republic of Slovenia, Ljubljana, Slovenia
Search for other papers by Ana Podbregar in
Google Scholar
PubMed
Department of Endocrinology, Diabetes and Metabolic Disease, University Medical Center Ljubljana, Ljubljana, Slovenia
Search for other papers by Tomaž Kocjan in
Google Scholar
PubMed
Department of Endocrinology, Diabetes and Metabolic Disease, University Medical Center Ljubljana, Ljubljana, Slovenia
Search for other papers by Matej Rakuša in
Google Scholar
PubMed
Clinical Institute of Radiology, University Medical Center Ljubljana, Ljubljana, Slovenia
Search for other papers by Peter Popović in
Google Scholar
PubMed
Clinical Institute of Radiology, University Medical Center Ljubljana, Ljubljana, Slovenia
Search for other papers by Manca Garbajs in
Google Scholar
PubMed
Search for other papers by Katja Goricar in
Google Scholar
PubMed
Department of Endocrinology, Diabetes and Metabolic Disease, University Medical Center Ljubljana, Ljubljana, Slovenia
Search for other papers by Andrej Janez in
Google Scholar
PubMed
Department of Endocrinology, Diabetes and Metabolic Disease, University Medical Center Ljubljana, Ljubljana, Slovenia
Search for other papers by Mojca Jensterle in
Google Scholar
PubMed
to January 2011 and were characterized as NFAI. NFAI was confirmed when cortisol after 1 mg overnight dexamethasone suppression test (ODST) was < 50 nmol/L, no typical clinical signs of Cushing’s syndrome were present and pheochromocytoma and primary
Search for other papers by Agnieszka Adamska in
Google Scholar
PubMed
Search for other papers by Vitalii Ulychnyi in
Google Scholar
PubMed
Search for other papers by Katarzyna Siewko in
Google Scholar
PubMed
Search for other papers by Anna Popławska-Kita in
Google Scholar
PubMed
Search for other papers by Małgorzata Szelachowska in
Google Scholar
PubMed
Search for other papers by Marcin Adamski in
Google Scholar
PubMed
Search for other papers by Angelika Buczyńska in
Google Scholar
PubMed
Clinical Research Centre, Medical University of Bialystok, Bialystok, Poland
Search for other papers by Adam Jacek Krętowski in
Google Scholar
PubMed
Cushing’s syndrome ( 9 ). The definition of MACS is based on the serum cortisol values after a 1 mg overnight dexamethasone suppression test (DST); however, the cut-off values are not clearly established ( 9 ). In the European Society of Endocrinology (ESE
Waikato Clinical Campus, University of Auckland, Hamilton, New Zealand
Search for other papers by M S Elston in
Google Scholar
PubMed
Search for other papers by V B Crawford in
Google Scholar
PubMed
Search for other papers by M Swarbrick in
Google Scholar
PubMed
Search for other papers by M S Dray in
Google Scholar
PubMed
Search for other papers by M Head in
Google Scholar
PubMed
Search for other papers by J V Conaglen in
Google Scholar
PubMed
–700 nmol/L Serum bicarbonate 36.3 22–26 mmol/L Venous pH 7.498 7.35–7.45 PSA 1.35 <6.5 ng/mL Initial endocrine evaluation Midnight cortisol >1655 <50 nmol/L 1 mg overnight dexamethasone suppression test
Search for other papers by Richard W Carroll in
Google Scholar
PubMed
Department of Medicine, University of Otago, Wellington, New Zealand
Search for other papers by Brian Corley in
Google Scholar
PubMed
Search for other papers by Joe Feltham in
Google Scholar
PubMed
Department of Medicine, University of Otago, Wellington, New Zealand
Search for other papers by Patricia Whitfield in
Google Scholar
PubMed
Search for other papers by William Park in
Google Scholar
PubMed
Search for other papers by Rowena Howard in
Google Scholar
PubMed
Search for other papers by Melissa Yssel in
Google Scholar
PubMed
Search for other papers by Ian Phillips in
Google Scholar
PubMed
Department of General Surgery, Wellington Regional Hospital, New Zealand
Search for other papers by Simon Harper in
Google Scholar
PubMed
Department of Medicine, Monash University, Clayton, Victoria, Australia
Search for other papers by Jun Yang in
Google Scholar
PubMed
41 (73%) patients, through the use of urinary free cortisol measurement in 9 out of 36 (25%) patients, midnight salivary cortisol measurements in 1 out of 36 (3%) patients, and an overnight dexamethasone suppression test in 21 out of 36 (58%) patients
Department of Medicine, Haukeland University Hospital, Bergen, Norway
Search for other papers by Grethe Å Ueland in
Google Scholar
PubMed
Search for other papers by Thea Grinde in
Google Scholar
PubMed
Department of Medicine, Haukeland University Hospital, Bergen, Norway
K. G. Jebsen Center for Autoimmune Disorders, University of Bergen, Bergen, Norway
Search for other papers by Paal Methlie in
Google Scholar
PubMed
Search for other papers by Oskar Kelp in
Google Scholar
PubMed
K. G. Jebsen Center for Autoimmune Disorders, University of Bergen, Bergen, Norway
Search for other papers by Kristian Løvås in
Google Scholar
PubMed
Department of Medicine, Haukeland University Hospital, Bergen, Norway
K. G. Jebsen Center for Autoimmune Disorders, University of Bergen, Bergen, Norway
Search for other papers by Eystein S Husebye in
Google Scholar
PubMed
therefore recommended that all patients with AI should be assessed for ACS. The most recent international guidelines recommend the 1 mg overnight dexamethasone suppression test (DST) to screen for ACS ( 1 ). This test is not optimal, as the DST has low
Search for other papers by Gamze Akkuş in
Google Scholar
PubMed
Search for other papers by Isa Burak Güney in
Google Scholar
PubMed
Search for other papers by Fesih Ok in
Google Scholar
PubMed
Search for other papers by Mehtap Evran in
Google Scholar
PubMed
Search for other papers by Volkan Izol in
Google Scholar
PubMed
Search for other papers by Şeyda Erdoğan in
Google Scholar
PubMed
Search for other papers by Yıldırım Bayazıt in
Google Scholar
PubMed
Search for other papers by Murat Sert in
Google Scholar
PubMed
Search for other papers by Tamer Tetiker in
Google Scholar
PubMed
mg of overnight dexamethasone suppression tests or 2 days of low-dose dexamethasone suppression test plus the following additional measurements; 24-h urinary free cortisol excretion (UFC), suppressed serum adrenocorticotrophic hormone (ACTH) levels
Search for other papers by Kuang Hung in
Google Scholar
PubMed
Search for other papers by Bo-Ching Lee in
Google Scholar
PubMed
Search for other papers by Po-Ting Chen in
Google Scholar
PubMed
Search for other papers by Kao-Lang Liu in
Google Scholar
PubMed
Department and Graduate Institute of Forensic Medicine, National Taiwan University College of Medicine, Taipei, Taiwan
Search for other papers by Chin-Chen Chang in
Google Scholar
PubMed
Search for other papers by Vin-Cent Wu in
Google Scholar
PubMed
Search for other papers by Yen-Hung Lin in
Google Scholar
PubMed
PA was confirmed by an LI value ≥ 2.0 ( 20 , 23 , 24 ). Screening for ACS The 1 mg overnight dexamethasone suppression test (DST) was performed to obtain the hypercortisolism status of the patients. Patients who failed to suppress cortisol